The advent of anti-VEGF therapy for cancer, specifically bevacizumab (IVB; Avastin; Genentech; South San Francisco, CA, USA), led to the use of the same drug in exudative AMD (eAMD) and was found to be highly effective. Here, VEGFA is linked to age-related macular degeneration.